20030-U
Gel de sílice activado ORBO™ 502 (20/45) 100/50 mg
W,W,F separators, O.D. × L 6 mm × 75 mm, pkg of 50 ea
Sinónimos:
ORBO™ Activated Silica Gel Tube
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
NACRES:
NB.24
UNSPSC Code:
12190000
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Segment
material
W,W,F separators, silica gel
agency
NIOSH 2000,5518
product line
ORBO™
composition
Bed A, 100 mg , Bed B, 50 mg
packaging
pkg of 50 ea
manufacturer/tradename
ORBO™ 502
technique(s)
active air sampling: suitable
O.D. × L
6 mm × 75 mm
matrix
activated silica gel
particle size
20-45 mesh
application(s)
air monitoring
environmental
industrial hygiene
General description
ORBO 502 Activated Silica Gel (20/45) 100/50 mg sorbent tubes (W,W,F separators, O.D. × L 6 mm × 75 mm) contain two beds of the same selective adsorbent separated by glass wool or foam, for gas and vapor sampling. The dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.
Legal Information
ORBO is a trademark of Sigma-Aldrich Co. LLC
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
A Orbo et al.
International journal of oncology, 5(3), 619-625 (1994-09-01)
About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as